Akava Therapeutics, Inc.

akava therapeutics, inc. was established in 2019 as a commercialization arm for the pipeline of compounds developed from the silverman lab at northwestern university. for 47 years, dr. richard b. silverman has been responsible for groundbreaking research, including inventing the blockbuster drug lyrica®, marketed by pfizer for fibromyalgia, neuropathic pain, spinal cord injury pain, and epilepsy. akava’s pipeline is a collection of the most exciting novel small molecule compounds emerging from the silverman laboratory. our mission is to discover and develop first-in-class inhibition therapeutics addressing unmet medical needs in neurodegeneration and oncology, allowing patients to live longer with improved quality of life. akava’s lead compound, akv9, is being developed for amyotrophic lateral sclerosis (als) and has also shown potential in mouse models of alzheimer’s disease (ad). akv9 was discovered using a mechanism-focused and cellular based drug discovery approach and is the